Literature DB >> 8235450

The detection and biological activity of human antibodies to IL-2 in normal donors.

L Tiberio1, A Caruso, A Pozzi, L Rivoltini, D Morelli, E Monti, A Balsari.   

Abstract

Antibodies to interleukin-2 (IL-2) have been reported in the sera of patients under therapies involving this cytokine and in the sera of patients infected with human immunodeficiency virus (HIV). Our study proves that auto-antibodies to IL-2 are present also, at a lower titre, in healthy individuals. These antibodies were affinity purified and studied for their capability to interfere with the in vitro biological activity of IL-2. Data obtained show that human anti-IL-2 antibodies can interfere with lymphocyte proliferation both in the lymphokine activated killer (LAK) cell assay and in the mixed lymphocyte reaction (MLR). However, the kinetics of inhibition by anti-IL-2 antibodies differs from LAK cell assay to MLR as the former are always inhibited in a time-independent manner, and the latter only by adding antibodies at the outset of culture. The neutralizing activity observed in vitro suggests that such antibodies play a part in the elaborate cytokine network by which the immune system regulates the amplitude and duration of its response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235450     DOI: 10.1111/j.1365-3083.1993.tb02590.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.

Authors:  A Meager; M Wadhwa; C Bird; P Dilger; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

2.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

3.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

4.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

5.  Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus.

Authors:  Miao Shao; Xiao-Lin Sun; He Sun; Jing He; Rui-Jun Zhang; Xia Zhang; Zhan-Guo Li
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

6.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.